P&G DIDROCAL PROSPECTIVE STUDY IN HIGH FRACTURE RISK OSTEOPOROSIS PATIENTS NEEDED, FDA CMTE. CONCLUDES; WIDESPREAD OFF-LABEL USE REPORTED
Executive Summary
Proctor & Gamble's osteoporosis treatment Didrocal needs positive efficacy data from a prospective clinical study in high-risk populations, FDA's Endocrinologic & Metabolic Drugs Advisory Committee indicated in its second evaluation of the bisphosphonate drug.
You may also be interested in...
UnitedHealth Disease Management Is Model For Medicare, Bush Says
UnitedHealth Group's EverCare disease management program is an example of the right approach to caring for seniors under Medicare, President Bush said during a speech in Minneapolis July 11
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011